DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2006 archives
Click here to return to the current data set

DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.

See Plans and Pricing

Generic Name: aripiprazole

Summary for Generic Name: aripiprazole

Tradenames:1
Patents:3
Applicants:1
NDAs:4
Drug Master File Entries: see list31
Suppliers: see list12
Therapeutic Class:Antipsychotics
Bipolar Agents

Tentative approvals for ARIPIPRAZOLE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET, ORALLY DISINTEGRATING; ORAL10MG
<disabled><disabled>TABLET, ORALLY DISINTEGRATING; ORAL15MG
<disabled><disabled>TABLET, ORALLY DISINTEGRATING; ORAL20MG

Clinical Trials for: aripiprazole

Aripiprazole and Topiramate on Free-Choice Alcohol Use
Status: Recruiting Condition: Alcohol Dependence

Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Status: Recruiting Condition: Major Depressive Disorder

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
Status: Completed Condition: Schizophrenia

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Status: Active, not recruiting Condition: Autism

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Status: Completed Condition: Major Depressive Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Litigation for: ARIPIPRAZOLE

  • OTSUKA PHARMACEUTICAL CO., LTD. v.

    • Glossary
    Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Patented / Exclusive Use
    Otsuka
    ABILIFY
    aripiprazole
    		INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes<disabled>NEW CHEMICAL ENTITY
    Otsuka
    ABILIFY
    aripiprazole
    		INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes<disabled>NEW DOSAGE FORM
    Otsuka
    ABILIFY
    aripiprazole
    		INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes5,006,528<disabled>ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
    Otsuka
    ABILIFY
    aripiprazole
    		INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes7,115,587<disabled>TREATMENT OF SCHIZOPHRENIA
    The preview shows a limited data set. Complete access is available with a Subscription
    first patents previous patents next patents last patents

    Export unavailable in trial.
    Subscribe for complete access.

    « Back to Dashboard

    Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

    Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

    Sign up for a free trial

    First name
    Last name
    Email address

    Connect with Social Media:

    Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

    Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639

    `abc